{"created":"2023-05-15T14:46:38.677427+00:00","id":63998,"links":{},"metadata":{"_buckets":{"deposit":"d6fe1880-e030-4b16-87f2-edbb6777cafa"},"_deposit":{"created_by":1,"id":"63998","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"63998"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00063998","sets":["10:29"]},"author_link":["631421","631419","631415","631418","631417","631420","631416","631422"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2010-09-11","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Purpose: An up-to-date analysis of the results of hypofractionated conformal carbon ion radiotherapy (C-ion RT) for localized prostate cancer was performed to determine the normal tissue morbidity, biochemical relapse-free rate (bNED), and patient survival. \nMethods and Materials:  Nine hundred and three prostate cancer patients who received the C-ion RT that had been established by two prior dose-escalation studies were analyzed with regard to toxicity, survival, and bNED. \nResults: Only 1 out of 818 patients followed up for at least 12 months developed grade 3 genitourinary toxicity, and no grade 3 or higher toxicities were observed in the rectum. The incidence of grade 2 rectum and GU morbidity were only 2.0% and 5.6%, respectively. The incidence of late toxicity in the patients treated with C-ion RT for 16 fractions was lower than that for patients who received 20 fractions. The overall bNED at 5 years was 90.9%, with only five local recurrences. The bNED of the 16-fraction C-ion RT was comparable to that of 20 fractions. The Gleason's score, T-stage, and initial PSA were significant prognostic factors for bNED, and the T-stage and initial PSA were also significant prognostic factors for the overall survival rate. C-ion RT with the established dose fractionation regimen yielded satisfactory bNED with very few local recurrences, and with minimal morbidity. Therefore, C-ion RT in 16 fractions could offer an even lower incidence of toxicities than 20 fractions, without any decrease in the biochemical control of the disease.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"The 4th Japanese-European Joint Symposium on Ion Cancer Therapy and KI-NIRS Joint Symposium on Ion-Radiation Sciences","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Tsuji, Hiroshi"}],"nameIdentifiers":[{"nameIdentifier":"631415","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Okada, Tohru"}],"nameIdentifiers":[{"nameIdentifier":"631416","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"631417","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsujii, Hirohiko"}],"nameIdentifiers":[{"nameIdentifier":"631418","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻 比呂志","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"631419","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"岡田 徹","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"631420","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鎌田 正","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"631421","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻井 博彦","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"631422","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Carbon Ion Radiotherapy for Prostate Cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Carbon Ion Radiotherapy for Prostate Cancer"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2010-09-14"},"publish_date":"2010-09-14","publish_status":"0","recid":"63998","relation_version_is_last":true,"title":["Carbon Ion Radiotherapy for Prostate Cancer"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T21:16:35.125616+00:00"}